Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Akbulut

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 1, 1996
Two dose levels of ifosfamide in malignant mesotheliomaF Içli, H Karaoğuz, S Hastürk, et al.
The International Journal of Biological Markers|December 21, 2006
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired studyM Dogan, A Demirkazik, N Konuk, et al.
Experimental Oncology|March 26, 2015
The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancerY Ürun, G Utkan, B Yalcin, et al.
Cancer|January 5, 1999
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology GroupF Içli, I Celik, F Aykan, et al.
Medical Oncology (Northwood, London, England)|January 8, 2010
Education, economic status and other risk factors in gastric cancer: "a case-control study of Turkish Oncology Group"F Icli, H Akbulut, B Yalcin, et al.
The International Journal of Biological Markers|February 17, 2017
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired studyM Dogan, A Demirkazik, N Konuk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancerF Içli, H Akbulut, D Dinçol, et al.
European Journal of Cancer Care|January 10, 2008
The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinomaO Sencan, A Buyukcelik, B Yalcin, et al.
Annals of the Royal College of Surgeons of England|October 30, 2016
The diagnostic ability of core needle biopsy in nodular thyroid diseaseE Aysan, T Kiran, U O Idiz, et al.
Cancer|May 17, 2000
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcomaD Dinçol, M Samur, A Pamir, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|September 1, 1996
Two dose levels of ifosfamide in malignant mesotheliomaF Içli, H Karaoğuz, S Hastürk, et al.
The International Journal of Biological Markers|December 21, 2006
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired studyM Dogan, A Demirkazik, N Konuk, et al.
Experimental Oncology|March 26, 2015
The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancerY Ürun, G Utkan, B Yalcin, et al.
Cancer|January 5, 1999
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology GroupF Içli, I Celik, F Aykan, et al.
Medical Oncology (Northwood, London, England)|January 8, 2010
Education, economic status and other risk factors in gastric cancer: "a case-control study of Turkish Oncology Group"F Icli, H Akbulut, B Yalcin, et al.
The International Journal of Biological Markers|February 17, 2017
The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospectivematched-paired studyM Dogan, A Demirkazik, N Konuk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancerF Içli, H Akbulut, D Dinçol, et al.
European Journal of Cancer Care|January 10, 2008
The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinomaO Sencan, A Buyukcelik, B Yalcin, et al.
Annals of the Royal College of Surgeons of England|October 30, 2016
The diagnostic ability of core needle biopsy in nodular thyroid diseaseE Aysan, T Kiran, U O Idiz, et al.
Cancer|May 17, 2000
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcomaD Dinçol, M Samur, A Pamir, et al.
Pageof 6